Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Taletrectinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer

    07 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007470241/en

    BUSINESSWIRE
    07 Oct 2024
    Share Share
    Nuvation Bio Reports Q2 2024 Results And Business Update
    Nuvation Bio Reports Q2 2024 Results And Business Update

    05 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240805155584/en

    BUSINESSWIRE
    05 Aug 2024
    Share Share
    Nuvation Bio Updates On ROS1 Inhibitor Taletrectinib
    Nuvation Bio Updates On ROS1 Inhibitor Taletrectinib

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723906535/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    Innovent's Taletrectinib ROS1 Inhibitor Data Published, Presented At ASCO
    Innovent's Taletrectinib ROS1 Inhibitor Data Published, Presented At ASCO

    02 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-taletrectinibros1-inhibitorupdated-data-from-pivotal-phase-2-trust-i-study-of-are-published-in-the-jco-and-orally-presentedat-2024-asco-annual-meeting-302161194.html

    PR NEWSWIRE
    02 Jun 2024
    Share Share
    Innovent's Taletrectinib ROS1 Inhibitor Pivotal Data Published, At ASCO
    Innovent's Taletrectinib ROS1 Inhibitor Pivotal Data Published, At ASCO

    01 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-data-from-pivotal-phase-2-trust-i-study-of-taletrectinibros1-inhibitor-are-published-in-the-jco-and-reported-at-2024-asco-annual-meeting-302161100.html

    PR NEWSWIRE
    01 Jun 2024
    Share Share
    Nuvation's Taletrectinib ROS1 Inhibitor Data Published In JCO, At ASCO
    Nuvation's Taletrectinib ROS1 Inhibitor Data Published In JCO, At ASCO

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240531690616/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share